Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

Adelphi Real World

Status: Enrolling

Conditions: Axial Spondylarthritis (axSpA); Psoriatic Arthritis (PsA)

Treatments: Other: observational study

Study type: Observational

Funder types: Industry

Identifiers

NCT07166315

AG9827

Details and patient eligibility

About

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Full description

Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.

Enrollment: 700 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
• Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
• Participant is aged 18 years or older at enrolment.

Exclusion criteria

-Participation in a clinical trial at enrolment.

Trial design

700 participants in 2 patient groups

Axial spondyloarthritis (axSpA)

Description:

Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.

Treatment:

Other: observational study

Psoriatic arthritis (PsA)

Description:

Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.

Treatment:

Other: observational study